Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Factor VIII Stories

2012-07-08 22:21:10

PARIS, July 9, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today reported data from its ongoing Phase 2/3 study evaluating the efficacy of OBI-1, an investigational recombinant porcine factor VIII (FVIII), for the treatment of serious bleeds in people with acquired hemophilia A. According to the interim analysis, seven out of seven trial participants receiving OBI-1 experienced control and subsequent resolution of their bleeds. Edward Gomperts, MD, Attending...

2012-07-07 22:20:15

WAYNE, N.J., July 8, 2012 /PRNewswire/ -- Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its investigational compound BAY94-9027 for the treatment of hemophilia A. The PROTECT VIII (PROphylaxis in hemophilia A patienTs via directly pEgylated long-aCTing rFVIII) trial is designed to investigate whether BAY94-9027, a recombinant human factor VIII (rFVIII), can prolong the duration of protection from bleeds and allow...

2012-07-06 23:03:42

New study “Global Hemophilia Market Report: 2012 Edition” developed by Koncept Analytics has been recently published by Market Publishers Ltd. According to the study, the global market for hemophilia products has shown continuous growth in the past years growing at 8.96% CAGR from 2006 to 2011 and is projected to expand steadily in the upcoming years. London, UK (PRWEB) July 06, 2012 The global market for hemophilia products has shown continuous growth in the past years growing...

2012-06-25 02:26:26

BEIJING, June 25, 2012 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. ("Taibang") has received a manufacturing approval certificate from the China State Food and Drug Administration ("SFDA") for Human Coagulation Factor VIII ("FVIII"). With this...

2012-06-21 23:03:15

Strategic focus and robust portfolio of services continue to create record distribution trend for specialty biotech distributor BDI Pharma. Columbia, SC (PRWEB) June 21, 2012 BDI Pharma, Inc. (BDI), the nation´s fastest growing national distributor of biotech therapies, after finishing the previous calendar year with a record level of distribution in anti-hemophilic factor (AHF), announced today that through the first five (5) months of 2012, the company´s distribution is tracking...

2012-06-08 02:23:54

KING OF PRUSSIA, Pa., June 8, 2012 /PRNewswire/ -- CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The Orphan Drug Designation is granted for the treatment and prophylaxis of bleeding episodes in patients with congenital factor IX deficiency (hemophilia B). The designation includes routine prophylaxis...

2012-02-24 13:00:00

VIENNA, Feb. 24, 2012 /PRNewswire/ -- CSL Behring has announced that the first patient has been screened in its recombinant coagulation single-chain factor VIII (rFVIII) trial, part of the AFFINITY clinical trial program. The CSL Behring rFVIII, called 'rVIII-SingleChain', is a novel molecule being studied for the treatment of hemophilia A. It is being developed by CSL Behring, in collaboration with its parent company, CSL Limited (ASX: CSL). "CSL is advancing at a very encouraging rate with...

2012-02-23 06:30:00

NES-ZIONA, Israel, Feb. 23, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today announced that PROLOR scientist Dr. Gili Hart will present data on its long-acting clotting factors in preclinical development for the treatment of hemophilia at the European Association for Haemophilia and Allied Disorders (EAHAD) 5th Annual Congress. Dr. Hart's presentation, "FVIIa-CTP and FIX-CTP, novel long-acting coagulation factors with prolonged hemostatic effect and improved recovery in...

2012-02-22 07:30:00

ROME, Feb. 22, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced clinical results for the Company's lead product candidate, an intravenous recombinant factor IX (FIX) product being investigated for the treatment and prevention of bleeding in individuals with hemophilia B. The data demonstrated that Inspiration's FIX product provided effective surgical hemostasis in people with hemophilia B undergoing major surgical procedures. The data were highlighted...

2012-02-16 07:00:00

KING OF PRUSSIA, Pa., Feb. 16, 2012 /PRNewswire/ -- CSL Behring announced today that the company has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its novel recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). The Orphan Drug Designation is granted for the treatment and prophylaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX. CSL Behring is...